The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

مواد مشابهة

• The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  بواسطة: Wan, Marilyn T., وآخرون
  منشور في: (2020)
• Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
  بواسطة: Syed, Maha N., وآخرون
  منشور في: (2021)
• Evaluation of the Frequency of “Not Relevant” Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis
  بواسطة: Barbieri, John S., وآخرون
  منشور في: (2020)
• Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
  بواسطة: Wan, Marilyn T., وآخرون
  منشور في: (2020)
• The Fundamental Pivot of Strategic Decision Making: Creativity
  بواسطة: Arastoo Towhidi
  منشور في: (2011-02-01)